Diabetes Care Devices and Drugs Market Size, Share, Growth Analysis, By Product(Blood glucose monitoring devices and Insulin delivery devices), By End use(Hospitals, Ambulatory surgery centres, Diagnostic centres, Home care), By Region - Industry Forecast 2025-2032

Global diabetes care devices and drugs market is highly competitive and fragmented. To maintain a competitive edge, global diabetes care devices major players are working on their market growth by introducing more innovative products that are easy to purchase the consumer and provide more innovative and painless solutions. The intensity of competition among players is high, each player is trying to develop a new device and offer it at a competitive price. Also, to increase their market shares, players are entering new markets, especially in emerging economies where demand is much higher than supply.

On March 24, 2022 Zyla Health is transforming the management of diabetes and related diseases through its technological innovation and continuum of care. Zyla has launched a joint offering with Accu-Chek, for Diabetics, a smart glucometer and continuous diabetes care under the authority of leading doctors and specialists that enables you to effectively manage a chronic condition like diabetes. The offer was launched on Amazon and Flipkart and is now available for users across the country to avail.

On March 11, 2021, Roche announced the launch of the new Accu-Chek Instant System, a new connected blood glucose monitoring (BGM) system, which supports and enables Roche's approach to integrated personalized diabetes management (iPDM).

Top Player's Company Profiles

• Novo Nordisk A/S
• Eli Lilly and Company
• Sanofi S.A.
• Merck & Co., Inc.
• Abbott Laboratories
• Becton, Dickinson and Company
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson Services, Inc.
• Medtronic plc
• Dexcom, Inc.
• Insulet Corporation
• Ypsomed AG
• Ascensia Diabetes Care Holdings AG
• Tandem Diabetes Care, Inc.
• Senseonics Holdings, Inc.
• B. Braun Melsungen AG
• Terumo Corporation
• AstraZeneca
• Boehringer Ingelheim International GmbH
• Novartis AG